New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
11:11 EDTILMN, DGX, GHDX, QGEN, MYGN, LHPiper sees ASCO positive for Myriad, Genomic, Illumina at Piper Jaffray
Piper Jaffray said it views the American Society of Clinical Oncology conference as positive for Myriad Genetics (MYGN), Genomic Health (GHDX) and Illumina (ILMN), neutral for QIAGEN (QGEN), and neutral-to-negative for Quest Diagnostics (DGX) and LabCorp (LH). Piper notes traffic for Quest and LabCorp booths was lower than Myriad, which it called the "clear winner" among the BRCA test providers.
News For MYGN;GHDX;ILMN;QGEN;DGX;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
10:03 EDTDGX, LHOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:12 EDTLHLabCorp initiated with an Outperform at JMP Securities
Subscribe for More Information
06:12 EDTDGXQuest Diagnostics initiated with a Market Perform at JMP Securities
March 26, 2015
10:04 EDTMYGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:07 EDTMYGNMyriad Genetics downgraded to Sell from Neutral at Goldman
Subscribe for More Information
March 25, 2015
10:00 EDTDGXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AB InBev (BUD) downgraded to Reduce from Overweight at HSBC... BreitBurn Energy (BBEP) downgraded to Sell from Neutral at UBS... DiamondRock (DRH) downgraded to Reduce from Neutral at SunTrust... Ethan Allen (ETH) downgraded to Hold from Buy at Gabelli... Felcor Lodging (FCH) downgraded to Neutral from Buy at SunTrust... Finish Line (FINL) downgraded to Neutral from Buy at B. Riley... Hannover Re (HVRRY) downgraded to Sell from Hold at Deutsche Bank... Hersha Hospitality (HT) downgraded to Reduce from Neutral at SunTrust... Host Hotels (HST) downgraded to Reduce from Neutral at SunTrust... ING Groep (ING) downgraded to Neutral from Buy at Goldman... Informatica (INFA) downgraded to Neutral from Buy at Mizuho... Kofax (KFX) downgraded to Hold from Buy at Canaccord... LRR Energy (LRE) downgraded to Sell from Neutral at UBS... LaSalle Hotel (LHO) downgraded to Reduce from Neutral at SunTrust... Munich Re (MURGY) downgraded to Sell from Hold at Deutsche Bank... Orbital ATK (OA) downgraded to Market Perform from Outperform at Wells Fargo... PCTEL, Inc. (PCTI) downgraded to Neutral from Buy at B. Riley... Quest Diagnostics (DGX) downgraded to Hold from Buy at Deutsche Bank... SJW Corp. (SJW) downgraded to Neutral from Outperform at RW Baird... Selective Insurance (SIGI) downgraded to Neutral from Buy at BofA/Merrill... Sonus (SONS) downgraded to Hold from Buy at Wunderlich... Starwood (HOT) downgraded to Neutral from Buy at SunTrust... Synchrony Financial (SYF) downgraded to Neutral from Buy at BofA/Merrill... Tesla (TSLA) downgraded to Underperform from Outperform at CLSA... Twitter (TWTR) downgraded to Hold from Buy at Pivotal Research... ZAGG (ZAGG) downgraded to Market Perform from Outperform at Northland... iDreamSky (DSKY) downgraded to Neutral from Overweight at JPMorgan.
08:53 EDTLHLabCorp has a conference call hosted by JPMorgan
Subscribe for More Information
07:12 EDTDGXQuest Diagnostics downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
March 24, 2015
08:30 EDTLHLabCorp shares should be bought at current levels, says Maxim
Subscribe for More Information
07:46 EDTLHLabCorp price target raised to $160 from $141 at Maxim
Subscribe for More Information
March 20, 2015
08:04 EDTGHDXGenomic Health reports positive data on positive impact of Oncotype DX test
Genomic Health announced that 11 studies were presented at the 14th St. Gallen International Breast Cancer Conference, including positive results from a real-life observational study in Ireland.1 That study demonstrated that use of the Oncotype DX® test in early-stage breast cancer led to a 58 percent net reduction in chemotherapy use, resulting in net cost savings of nearly EUR 800,000, or approximately EUR 1,200 in cost savings per patient.
07:41 EDTMYGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 18, 2015
08:33 EDTILMNTrovagene appoints Matthew Posard as Chief Commercial Officer
Subscribe for More Information
March 17, 2015
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
March 16, 2015
16:07 EDTQGENTokai Pharmaceuticals expands collaboration with QIAGEN
Subscribe for More Information
16:06 EDTQGENQIAGEN acquires circulating tumor cell technology from AdnaGen
QIAGEN (QGEN) announced an expansion of itsportfolio of liquid biopsies through the acquisition of an technology that enables enrichment and molecular analysis of circulating tumor cells from blood samples. The proprietary technology from AdnaGen allows a complete solution for the detection and analysis of CTCs for clinical applications. QIAGEN also announced a new partnership with Tokai Pharmaceuticals (TKAI) to combine this new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer. The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies has demonstrated potential utility to guide therapy choice in CRPC patients. Financial terms for the AdnaGen acquisition and the Tokai partnership were not disclosed.
05:40 EDTILMNIllumina files patent infringement suit in UK regarding NIPT patents
Illumina (ILMN) announced that it and its wholly-owned subsidiary, Verinata Health have filed a patent infringement suit against Premaitha Health in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent 0 994 963 B2 and European Patent 1 981 995 B1, which are exclusively licensed to Illumina from Sequenom (SQNM), and The Board of Trustees of Leland Stanford Junior University, respectively. Stanford is joined in the suit as a necessary party because it is the registered owner of the European Patent 1 981 995 B1. The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing. The suit accuses Premaitha’s IONA Test of infringement, including its use of next-generation sequencing to analyze cell-free fetal DNA from a sample of maternal blood.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use